AD can be confirmed using cerebrospinal fluid (CSF) measures of amyloid and total tau concentrations, as well as tau Threonine 181 phosphorylation (P-T181) which is typically above physiological thresholds in AD patients11–13. This evidence concerns the gene MAPT and amyloidosis.